These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 21729661)
41. Trastuzumab emtansine: a review of its use in patients with HER2-positive advanced breast cancer previously treated with trastuzumab-based therapy. Dhillon S Drugs; 2014 Apr; 74(6):675-86. PubMed ID: 24659374 [TBL] [Abstract][Full Text] [Related]
42. Sortase-catalyzed in vitro functionalization of a HER2-specific recombinant Fab for tumor targeting of the plant cytotoxin gelonin. Kornberger P; Skerra A MAbs; 2014; 6(2):354-66. PubMed ID: 24492291 [TBL] [Abstract][Full Text] [Related]
45. Targeted therapy in rare cancers--adopting the orphans. Munoz J; Kurzrock R Nat Rev Clin Oncol; 2012 Nov; 9(11):631-42. PubMed ID: 22965154 [TBL] [Abstract][Full Text] [Related]
46. The promise of anti-ErbB3 monoclonals as new cancer therapeutics. Aurisicchio L; Marra E; Roscilli G; Mancini R; Ciliberto G Oncotarget; 2012 Aug; 3(8):744-58. PubMed ID: 22889873 [TBL] [Abstract][Full Text] [Related]
47. High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production. Thon JN; Devine MT; Jurak Begonja A; Tibbitts J; Italiano JE Blood; 2012 Sep; 120(10):1975-84. PubMed ID: 22665936 [TBL] [Abstract][Full Text] [Related]
48. Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology. Raschi E; De Ponti F Intern Emerg Med; 2012 Apr; 7(2):113-31. PubMed ID: 22161318 [TBL] [Abstract][Full Text] [Related]
49. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review. Mathew J; Perez EA Curr Opin Oncol; 2011 Nov; 23(6):594-600. PubMed ID: 21986845 [TBL] [Abstract][Full Text] [Related]
50. Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer. Burris HA; Tibbitts J; Holden SN; Sliwkowski MX; Lewis Phillips GD Clin Breast Cancer; 2011 Oct; 11(5):275-82. PubMed ID: 21729661 [TBL] [Abstract][Full Text] [Related]
51. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Krop I; Winer EP Clin Cancer Res; 2014 Jan; 20(1):15-20. PubMed ID: 24135146 [TBL] [Abstract][Full Text] [Related]
52. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Hurvitz SA; Dirix L; Kocsis J; Bianchi GV; Lu J; Vinholes J; Guardino E; Song C; Tong B; Ng V; Chu YW; Perez EA J Clin Oncol; 2013 Mar; 31(9):1157-63. PubMed ID: 23382472 [TBL] [Abstract][Full Text] [Related]
53. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893 [TBL] [Abstract][Full Text] [Related]
54. Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer. Niculescu-Duvaz I Curr Opin Mol Ther; 2010 Jun; 12(3):350-60. PubMed ID: 20521224 [TBL] [Abstract][Full Text] [Related]
55. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. Diéras V; Harbeck N; Budd GT; Greenson JK; Guardino AE; Samant M; Chernyukhin N; Smitt MC; Krop IE J Clin Oncol; 2014 Sep; 32(25):2750-7. PubMed ID: 25024070 [TBL] [Abstract][Full Text] [Related]